NOTE: This list will be continually updated. To submit your release, please email Sarah Ellinwood (media@biobuzz.io)
BioHealth Capital Region (Maryland, Virginia, and DC)
- NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
- NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting
- Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
- Arcellx Announces Presentation Of New Clinical Data From Its CART-DdBCMA Phase 1 Trial In Patients With Relapsed Or Refractory Multiple Myeloma At The 64th ASH Annual Meeting And Exposition
- I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
- Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
- Elixirgen Therapeutics to Present New Data Showing Successful Ex Vivo Telomere Elongation with EXG-34217 in a Phase 1/2 Clinical Trial at the 64th ASH Annual Meeting
Greater Philadelphia
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
- More Than 50 Abstracts From Incyte’s Robust Oncology Portfolio To Be Featured At The 64th ASH Annual Meeting
- Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
